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surgery irrespective of whether or not a rethoracotomy,
which involves higher in-hospital costs, has to be per-
formed following hemorrhage. In order to evaluate the
in-hospital costs for CABG with and without rethoracot-
omy from the hospital perspective, a cost-analysis of
CABG surgery was performed. Furthermore, the cost-
effectiveness of prophylactic administration of the anti-
hemorrhagic agent aprotinin was investigated. METH-
ODS: The detailed resource utilization of 138 CABG
patients, 68 with rethoracotomy and 70 without, was
analysed based on sample of patient medical records
from 7 German hospitals. Resource costs were provided
by hospital administrations and supplemented by litera-
ture. The overall costs for both groups were then com-
bined with rethoracotomy rates in patients with and
without prophylactic administration of aprotinin derived
from a published meta-analysis of all relevant clinical tri-
als in open heart surgery. RESULTS: The total in-hospi-
tal costs per patient with CABG were on average DM
21,241 and increased to DM 31,326 for a CABG patient
requiring rethoracotomy. Besides the costs of the rethora-
cotomy, the costs of intensive care were the main cost
driver in patients with rethoracotomy. The meta-analysis
showed with statistical significance that aprotinin can re-
duce the rethoracotomy rate from 5.0% to 1.8% in pa-
tients undergoing heart surgery. When combining the
cost data with the results of the meta-analysis, the ex-
pected average costs per patient treated with aprotinin
(including drug costs) were DM 21,432 compared to DM
21,655 per patient without aprotinin treatment. A cost-
effectiveness analysis (costs per patient without rethora-
cotomy) resulted in a difference of DM 970 in favour of
the prophylactic antihemorrhagic treatment. CONCLU-
SION: The analysis showed that CABG patients requir-
ing an additional rethoracotomy generated about 47%
higher costs than patients with CABG surgery only. The
administration of the antihemorrhagic agent aprotinin
can be recommended in the light of the reduced compli-
cation rate and improved cost-effectiveness of CABG-sur-
gery.
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The use of glycoprotein 2b/3a receptor antagonists has
been shown to be beneficial in elective coronary stent im-
plantation. In Canada, the cost of abciximab has limited
widespread use in this population. Recently presented
data comparing eptifibatide with heparin alone in a simi-
lar population has suggested a significant improvement in
clinical outcomes with this less expensive agent. There
are no trials directly comparing these two agents in the
elective stent patient population. OBJECTIVE: the pur-
pose of this study was to assess the cost-effectiveness of
abciximab or eptifibatide compared to standard therapy
in patients undergoing elective stent placement in a Cana-
dian setting using a decision analysis model. METHODS:
Clinical outcome data was abstracted from the Epistent
and Esprit trials. Economic data assessing direct costs for
coronary intervention procedures and complications was
acquired from the London Health Sciences Centre hospi-
tal cost database for the period 1998–99. The composite
clinical endpoint was freedom from death, myocardial in-
farction and urgent revascularization at 30 days. The pri-
mary study outcome was the incremental cost per event
prevented. RESULTS: In the baseline analysis, both
agents compared favorably with standard therapy. Ab-
ciximab had an incremental cost-effectiveness of $US
10,320 per event prevented. Eptifibatide was less costly
and more effective, hence dominant over standard ther-
apy. The baseline analysis yielded a benefit of 6 events
per 1,000 patients treated in favour of abciximab over
eptifibatide. However the incremental cost per event pre-
vented was $US 125,218, a less favorable value. CON-
CLUSION: The incremental cost-effectiveness of abcix-
imab compared to eptifibatide was sensitive to the cost of
abciximab and to the incidence of myocardial infarctions.
A randomized trial comparing abciximab and eptifi-
batide in elective coronary stent placement is necessary to
better assess this issue.
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OBJECTIVES: Cost-effectiveness studies can provide
valuable information for decision-making processes,
where limited resources need to be allocated across a va-
riety of different treatments. However, it is argued that
the current methods for conducting and reporting cost-
effectiveness results for this purpose are sub-optimal.
This literature review and analysis compares the most re-
cent hypertension cost-effectiveness studies. The goal is
to contribute information so that future cost-effectiveness
studies of hypertension treatments will provide more
optimal information for clinicians and other decision-
makers for the choice of antihypertensive treatment.
METHOD: A literature search of several databases for
the years 1995–2000 was conducted using the following
keywords: hypertension and cost-effectiveness and/or
economics. RESULTS: The search resulted in 89 articles,
of which only 11% (10 studies) were true pharmacoeco-
nomic studies that contained actual data analysis. Of the
10 studies, the majority reported outcome measures in
terms of cost per life year gained, but usually considered
more than one outcome measure. Coronary heart dis-
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eases and stroke were the most consistent endpoints
across the studies but the number and types of endpoints
that were included differed significantly among the stud-
ies. Only two studies included within-clinical trial treat-
ment effectiveness data, whereas the remaining studies
modeled treatment effects from previously published tri-
als. The projected cardiac event rates and life expectancy
were most often derived and estimated from the Framing-
ham study. Treatment costs were obtained from several
different sources outside clinical trials, and only one
study considered costs solely from the trial. CONCLU-
SION: Despite the increasing emphasis on hypertension
as one of the most costly long-term diseases, and the need
to reduce costs associated with it, there are relatively few
recently published studies on the cost-effectiveness of an-
tihypertensive therapies. Methodologically, these pub-
lished studies are very different and they do not seem to
agree on a common way to provide a cost-effectiveness
measure for hypertension treatment, making interpreta-
tions and comparability of results across different studies
more difficult.
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OBJECTIVE: To determine compliance and persistence
with cholesterol-lowering therapy with HMG-CoA re-
ductase inhibitors (statins) in patients following a myo-
cardial infarction (MI) or other atherosclerotic event.
METHODS: Patients were identified from a Midwestern
managed care organization (MCO) database who had an
MI or other atherosclerotic event in 1997 or 1998 and
were continuously enrolled in the MCO for the year fol-
lowing the event. Patient records were collected following
HEDIS reporting guidelines. Pharmacy claims data re-
view identified 216 patients who had at least one pre-
scription filled for a statin. Compliance and persistence
were assessed using length of therapy, single-interval
medication availability, multiple-refill-interval medica-
tion availability, single-interval medication gaps, and
multiple-refill-interval medication gaps. RESULTS: The
population was predominantly male (76%) and the mean
age was 61 years (SD 10.2 years, range 34 to 77). The
cardiovascular events were as follows: 52% MI, 45%
coronary atherosclerosis, and 4% other atherosclerotic
event. The proportion of patients persistent with statin
therapy at 3, 6, 9, and 12 months were 88, 86, 80, and
69 percent respectively. Patients achieved 90% compli-
ance with each refill (SD 25%, median 94) and cumula-
tive compliance for all refills was 83% (SD 24%, median
92). The average single-interval treatment gap was 11
days (SD 28.5 days, median 2 days) while the average cu-
mulative total treatment gap over the study period was
44 days (SD 70 days, median 13 days). CONCLUSIONS:
Compliance with HMG-CoA reductase inhibitors as
measured by single-interval and multiple-refill-interval
was generally high, but not ideal (100%) following an
MI or other atherosclerotic event. These pharmacy claims
data may be further analyzed using multivariate regres-
sion to determine the impacts of age, sex, diagnosis, num-
ber of concomitant medications, medication days supply,
type of statin prescribed, and patient copay on compli-
ance and persistence with therapy.
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OBJECTIVE: There are now a host of HMG-CoA reduc-
tase inhibitors (statins) for treating persons with elevated
cholesterol levels. The objective of this is to determine the
relative cost of treatment among statins. METHODS:
The ACCESS study was a 54-week open label trial of
atorvastatin as compared to fluvastatin, lovastatin, sim-
vastatin and pravastatin. After a screening phase and a
lead-in phase, patients were treated to NCEP target LDL-C
levels with statins, starting at the lowest dose level. At
six-week intervals (weeks 6, 12, 18) patients who had not
yet reached their LDL-C target were titrated up to the
next dose level, to a maximum of 40–80 mg, depending
on the statin. Costs of services used were recorded, in-
cluding: study medications, physician visits, laboratory
and diagnostic tests associated with cholesterol treatment
and other medical services associated with adverse
events. RESULTS: A total of 3916 patients were enrolled
in ACCESS, with 3262 patients completing the study. Pa-
tients treated with atorvastatin had the highest rate of
NCEP goal achievement (76.3% v. 34.2%–57.9%; P 
0.01 for each comparison). As a result of NCEP goal
achievement, atorvastatin-treated patients required the
fewest physician visits through weeks 6–18 (2.81 v. 2.95–
3.45; p  0.01 for each comparison) and the lowest di-
rect study cost per patient achieving NCEP goal ($915 v.
$1393–$2421; p  0.01 for each comparison)—the ulti-
mate measure of cost-effectiveness. CONCLUSIONS:
The ACCESS trial demonstrates that treatment with ator-
vastatin yielded the highest proportion of patients reach-
ing NCEP LDL-C goals at the lowest cost per patient.
